Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation and interleukin-2 in treating patients who have acute leukemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Herbert Irving Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Aldesleukin; Busulfan; Cyclophosphamide; Etoposide; Melphalan

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed acute leukemia

• High-risk due to any of the following:

• Cytogenetic abnormalities involving 5q, 7q, 8q, 11q23, or t(9;22)

• WBC greater than 100,000/mm3

• Prior myelodysplastic syndrome

• Complete remission (CR) lasting less than 12 months

• No favorable cytogenetic parameters (e.g., t(15;17), inv16, or t(8;21))

• CR following standard anti-leukemic therapy confirmed by bone marrow evaluation

• Second and third CR allowed

• Ineligible for higher priority national or institutional study or allogeneic peripheral blood stem cell transplantation

PATIENT CHARACTERISTICS:

Age:

• Any age

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• See Disease Characteristics

Hepatic:

• Bilirubin less than 1.5 times normal

• SGOT or SGPT less than 1.5 times normal

Renal:

• Creatinine less than 1.5 times normal

Cardiovascular:

• LVEF at least 45% if receiving cyclophosphamide

• Normal electrocardiogram OR

• Approval by cardiologist

Pulmonary:

• DLCO less than 60% predicted OR

• Approval by pulmonologist

Other:

• Not pregnant or nursing

• No concurrent illness that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified